High Court Won't Mull Punitives In Drug Labeling Suits

Law360, New York (October 7, 2013, 6:49 PM EDT) -- The U.S. Supreme Court declined Monday to consider Novartis Pharmaceutical Corp.'s contention that federal law preempts the awarding of punitive damages for the legal marketing of prescription drugs, keeping in place a $1.2 million verdict against the drugmaker.

Novartis argued in a petition for writ of certiorari filed in May that the Fourth Circuit never should have upheld a verdict in favor of plaintiff Herbert Fussman, whose late wife, Rita, was allegedly disfigured by Novartis' bone drugs Aredia and Zometa. State punitive damage awards encroach on...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.